NCT06169059

To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004

A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Jeil Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and pharmacokinetic characteristics after multiple administration of JC-013 and JLP-2004

Detailed description

A phase 1 clinical trial to compare and evaluate the safety and pharmacokinetic characteristics after multiple administration of JC-013 and JLP-2004 in healthy adult volunteers

Conditions

• Healthy Adult

Interventions

Type	Name	Description
DRUG	JLP-2004	administration of JLP-2004(COX-2 inhibitor)
DRUG	JC-013	administration of JC-013(COX-2 inhibitor))

Timeline

• Start date: 2023-10-05
• Primary completion: 2023-11-08
• Completion: 2023-11-19
• First posted: 2023-12-13
• Last updated: 2023-12-13

Locations

1 site across 1 country: South Korea